posted on 2022-02-24, 16:07authored byJustin
M. Rosenbohm, Catherine M. Klapperich, Mario Cabodi
Quantitative nucleic acid amplification testing (NAAT) is a key
enabling technology for infectious disease management, especially
in instances where viral load informs therapeutic decisions. Inadequate
access to quantitative NAATs remains a challenge to the successful
deployment of antiretroviral therapy (ART) regimens for patients with
chronic hepatitis B virus (CHB) in low resourced settings (LRS). Current
field-deployable NAATs are generally qualitative (yes/no) rather than
quantitative in nature, making them ill-suited for viral load monitoring
programs for CHB patients. Here, we report the development of a proof-of-concept
molecular diagnostic test, the semiquantitative ligation and amplification
(SQLA) assay, which achieves semiquantitative detection of input target
DNA at two independently tunable detection thresholds with a simple
visual readout. The SQLA assay utilizes a duplex competitive thermophilic
helicase-dependent amplification (tHDA) chemistry and can be performed
in under 1 h.